Kardigan

“Kardigan raised $400 million in an upsized IPO and saw its shares rise as much as 31% in its Nasdaq debut.”

“Kardigan set IPO terms targeting a $1.6B fully diluted value; backed by Arch Venture Partners, Perceptive, Fidelity, T. Rowe Price, and Sequoia Heritage.”

“Kardigan, a South SF-based cardiovascular drug developer, filed for a $100m IPO... raised over $550m from Arch, Fidelity, T. Rowe, Sequoia Heritage.”